CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript Summary
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript Summary
Significant decrease in revenues over nine months to $351,000 in 2024 from $10.7 million in 2023, primarily due to a milestone payment in the previous year.The following is a summary of the CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript:
以下是CollPlant生物技術有限公司（CLGN）2024年第三季度業績會議記錄摘要：
Financial Performance:
財務表現：
CollPlant reported Q3 2024 revenue of $4,000, a significant decrease from $43,000 in Q3 2023.
The GAAP net loss for Q3 2024 was $4.3 million or $0.38 basic loss per share, similar to Q3 2023.
Significant decrease in revenues over nine months to $351,000 in 2024 from $10.7 million in 2023, primarily due to a milestone payment in the previous year.
CollPlant報告2024年第三季度營業收入爲$4,000，較2023年第三季度的$43,000大幅下降。
2024年第三季度的按照美國通用會計準則（GAAP）的淨虧損爲$430萬（或每股基本虧損$0.38），與2023年第三季度類似。
2024年前九個月營業收入大幅下降至$35.1萬，主要原因是前一年的里程碑付款，而2023年爲$1070萬。
Business Progress:
業務進展：
Advanced the preclinical study of a regenerative breast implant program using proprietary rhCollagen and 3D printing technology.
Collaboration with AbbVie on a regenerative dermal and soft tissue filler product in the medical aesthetics market continues.
Showcased technology at the International Society for Biofabrication, gaining interest for new collaborations.
使用專有的rhCollagen和3d打印技術推進了再生性乳房植入計劃的臨床前研究。
與艾伯維公司在醫學美容市場上的再生皮膚及軟組織填充產品的合作持續進行。
在國際生物印刷協會展示了科技，引起了新合作伙伴的興趣。
Opportunities:
機會：
The market for breast implants, valued at approximately $3 billion, is projected to grow to about $6.5 billion by 2033.
The aesthetic filler market is valued at approximately $5.5 billion, expected to grow annually by 10%.
價值約30億美元的乳房植入物市場預計到2033年將增長到約65億美元。
美容填充劑市場價值約55億美元，預計年增長率爲10%。
Risks:
風險：
The company's financial stability could be at risk with a significant decrease in annual revenue and increased reliance on milestone payments and partnerships for revenue generation.
公司的財務穩定性可能會受到年度營業收入顯著減少以及對里程碑付款和合作夥伴關係增加依賴對營業收入產生影響的風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
